Publications: Dr Paul Harrow

Back to Search

McCarthy N, Gordon H, Rahman S, Harrow P, Stagg A, Lindsay J (2017). Mucosal inflammation promotes activation of circulating Vd2+T-cells in Crohn's disease. JOURNAL OF CROHNS & COLITIS. vol. 11, S107-S107.

McCarthy N, Gordon H, Rahman S, Harrow P, Stagg A, Lindsay J(2017). P059 Mucosal inflammation promotes activation of circulating Vδ2+ T-cells in Crohn's disease. J Crohns Colitis vol. 11, (suppl_1)

10.1093/ecco-jcc/jjx002.185

Harrow P, Skinner C, Hoque T, Ibarra A, Lindsay J (2016). DOSE OPTIMISATION USING DRUG AND ANTIBODY LEVELS CAN BENEFIT 50% PATIENTS PRESCRIBED ANTI TNF THERAPY COMPARED TO EMPIRIC DOSE ADJUSTMENT. GUT. vol. 65, A85-A86.

10.1136/gutjnl-2016-312388.153

Harrow P, Skinner C, Hoque T, Ibarra A, Lindsay J (2016). Dose optimisation using drug and antibody levels can benefit 50% patients prescribed anti-TNF therapy compared with empiric dose adjustment. JOURNAL OF CROHNS & COLITIS. vol. 10, S71-S72.

Parisinos CA, Harrow P, Langmead L, van Heel DA, Lindsay JO(2015). eHealth optimises documentation and enables live access to IBD Multi Disciplinary Team outcomes. JOURNAL OF CROHNS & COLITIS vol. 9, S366-S367.

Back to Search